KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Prognostic value of interim CT-based peritumoral and intratumoral radiomics in laryngeal and hypopharyngeal cancer patients undergoing definitive radiotherapy. PMID 37806562 · Radiother Oncol · 2023-Dec The study is a randomized trial in oncology with human patients and time-to-event endpoints, but it does not meet the drug intervention criterion. The intervention is definitive radiotherapy, which is non-drug. Additionally, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and it cannot be inferred.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Colorectal Cancer Knowledge and Screening Change in African Americans: Implementation Phase Results of the EPICS Cluster RCT. PMID 37790949 · AJPM Focus · 2023-Dec The study is a randomized, cluster-RCT of educational interventions to increase colorectal cancer screening in humans. It is oncology-related. However, it does not involve a drug-containing intervention (non-drug_only) and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). The primary endpoint is screening uptake (odds ratio).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial. PMID 37777685 · Ann Surg Oncol · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis. PMID 37775349 · Clin Breast Cancer · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass). PMID 37758574 · Eur Urol · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. PMID 37751000 · Clin Rheumatol · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study. PMID 37747668 · Radiol Med · 2023-Dec The record describes a retrospective, multicenter study developing a predictive nomogram for early recurrence after surgery in combined hepatocellular-cholangiocarcinoma. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The primary endpoints are predictive accuracy metrics (AUC, DCA, calibration) for recurrence, not a time-to-event efficacy analysis (e.g., Kaplan-Meier curve, hazard ratio). The 'randomized' tag in publication_types refers to the random division of patients into training/testing sets for model development, not to a randomized controlled trial design. Therefore, it does not meet the core eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study. PMID 37743180 · Clin Lymphoma Myeloma Leuk · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study. PMID 37738268 · Acta Oncol · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. PMID 37704538 · Clin Colorectal Cancer · 2023-Dec The report is a secondary pharmacokinetic analysis from the CO.20 trial. While it is oncology, human, randomized, drug-interventional, and reports time-to-event data (OS), it does not appear to be the primary result report of the Phase III/IIIb or Phase II/III randomized trial. The phase is not explicitly confirmed in the metadata, and the analysis focuses on a correlational subgroup (plasma concentration tertiles) rather than the primary trial comparison. Therefore, it is excluded as a secondary/exploratory analysis, not the original primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder? PMID 37704483 · Clin Genitourin Cancer · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial. PMID 37703995 · Transplant Cell Ther · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. PMID 37701986 · Future Oncol · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. PMID 37698371 · Pharmacotherapy · 2023-Dec The study is a randomized trial in a cancer population with a drug intervention (opioid), but it is an implementation-effectiveness trial focused on CYP2D6-guided pain management, not a Phase III/IIIb or Phase II/III trial of a malignant neoplasm with a time-to-event efficacy endpoint. It lacks the required primary efficacy endpoint (OS, PFS, etc.) and definitive trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). PMID 37690320 · Breast · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial. PMID 37670122 · Ann Surg Oncol · 2023-Dec The record is a subgroup analysis (racial disparities) within a Phase III randomized trial (NSABP B-42). While the trial itself is Phase III, oncology, human, randomized, has a drug intervention, and a time-to-event endpoint (LRR), this specific publication is not an original formal report of the primary or key secondary trial results. It is a secondary analysis focusing on a specific subgroup question, thus not eligible as per the inclusion criteria for primary trial result reports.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. PMID 37482512 · Eur Urol · 2023-Dec This is a Phase 3 prospective imaging trial of prostate cancer, but it is not randomized, does not involve a drug-containing intervention (it evaluates an imaging modality), and the primary efficacy endpoint is biochemical recurrence-free survival, which is a time-to-event outcome; however, the report focuses on prognostic value and risk assessment via Cox models and c-statistics, not on reporting KM curves or HR for comparing treatment groups. It lacks the required drug intervention and standard time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a therapeutic RCT.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial. PMID 37470132 · BJU Int · 2023-Dec The study is a randomized oncology trial in humans with a drug intervention (neoadjuvant chemotherapy) component, but it does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary outcomes are surgical quality composites (pentafecta, trifecta) and health-related quality of life, not a Kaplan-Meier or HR-based time-to-event analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission. PMID 37395196 · Ann Med · 2023-Dec The study is a retrospective prognostic analysis of routine blood tests in breast cancer patients with bone metastasis. It is not a randomized clinical trial of a drug intervention. The 'randomized' publication type is a misclassification; patients were randomly split into training/validation cohorts for nomogram development, not randomized to treatments. There is no drug intervention, no Phase III evidence, and the endpoint is not a trial efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endoscopic full-thickness resection versus endoscopic submucosal dissection for challenging colorectal lesions: a randomized trial. PMID 37390864 · Gastrointest Endosc · 2023-Dec The record describes a randomized trial of endoscopic procedures (EFTR vs ESD) for colorectal lesions. It is a human oncology study with original results. However, it does not involve a drug-containing intervention, and it reports procedural/safety outcomes (R0 resection, procedure time, adverse events) rather than the required time-to-event efficacy endpoints (e.g., OS, PFS, DFS, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest. PMID 37341303 · J Dermatolog Treat · 2023-Dec The record is for a non-oncology condition (psoriasis) and is a safety-only analysis, not an efficacy trial with a time-to-event endpoint like OS, PFS, etc.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-initiated follow-up in women with early-stage endometrial cancer: A long-term follow-up of the OPAL trial. PMID 37277320 · BJOG · 2023-Dec This is a randomized trial in human oncology (early-stage endometrial cancer), but it compares follow-up strategies (patient-initiated vs. hospital-based), not a drug-containing intervention. The endpoints are patient-reported outcomes (fear of recurrence, quality of life) and healthcare use, not time-to-event efficacy endpoints like OS, PFS, DFS, etc. Therefore, it does not meet the core eligibility criteria for drug intervention and time-to-event endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparing the efficacy of oral labetalol with oral amlodipine in achieving blood pressure control in women with postpartum hypertension: randomized controlled trial (HIPPO study-Hypertension In Pregnancy & Postpartum Oral-antihypertensive therapy). PMID 37231139 · J Hum Hypertens · 2023-Dec The study is a randomized controlled trial with a drug intervention and a primary efficacy endpoint, but it is not an oncology study. It evaluates antihypertensive medications (labetalol vs. amlodipine) for postpartum hypertension, which is not a malignant neoplasm. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial. PMID 37019717 · J Thorac Cardiovasc Surg · 2023-Dec This is a randomized Phase III trial of a drug-containing intervention (pafolacianine) for oncology in humans, with original results. However, the primary endpoint is the proportion of participants with a clinically significant event (a surgical outcome measure), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Estimating optimal individualized treatment rules with multistate processes. PMID 37015010 · Biometrics · 2023-Dec The record is an original methodological paper using data from an oncology RCT, but it does not explicitly report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) for a drug intervention. The focus is on statistical methodology, not clinical trial results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology. PMID 36867373 · Ir J Med Sci · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies. PMID 36652155 · J Gastrointest Cancer · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis. PMID 36305624 · J Dermatolog Treat · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of an intravenous lidocaine bolus before tracheal extubation on recovery after breast surgery - Lidocaine at the End (LATE) study: a randomized controlled clinical trial. PMID 37654034 · Croat Med J · 2023-Aug-31 The study is a randomized controlled trial with a drug intervention and original results, but it is not a Phase III/IIIb or Phase II/III oncology trial, and it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The endpoints are postoperative recovery metrics (emergence quality, coughing, sore throat, PONV), which are not time-to-event efficacy outcomes in oncology.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial. PMID 37653589 · Cancer Biol Med · 2023-Aug-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment. PMID 37650478 · Cochrane Database Syst Rev · 2023-Aug-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China. PMID 37691869 · Transl Lung Cancer Res · 2023-Aug-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Omega-3 nanoemulgel in prevention of radiation-induced oral mucositis and its associated effect on microbiome: a randomized clinical trial. PMID 37648997 · BMC Oral Health · 2023-Aug-30 The study is an oncology randomized trial in humans with original results, but it does not meet the core eligibility criteria: (1) The intervention is a topical omega-3 nanoemulgel (a nutraceutical/supplement), not a standard drug intervention; (2) The primary endpoints are symptom scores (VAS, WHO grade, QoL) and microbiome changes, not a time-to-event efficacy endpoint; (3) The trial phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103. PMID 37340766 · Jpn J Clin Oncol · 2023-Aug-30 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Comparison between laparoscopic-assisted natural orifice specimen extraction surgery and conventional laparoscopic surgery for left colorectal cancer: 5-year follow-up results of a randomized controlled study]. PMID 37574293 · Zhonghua Wei Chang Wai Ke Za Zhi · 2023-Aug-25 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). PMID 36201360 · Mod Rheumatol · 2023-Aug-25 The study is a phase III randomized trial with a drug intervention, but it evaluates a non-oncology condition (rheumatoid arthritis) and reports efficacy primarily via ACR response rates and other clinical assessments, with no signal of a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial). PMID 36197757 · Mod Rheumatol · 2023-Aug-25 The study is a randomized, Phase II/III trial in rheumatoid arthritis (non-oncology) with a drug intervention and an original result report, but it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Argipressin for prevention of blood loss during liver resection: a study protocol for a randomised, placebo-controlled, double-blinded trial (ARG-01). PMID 37620260 · BMJ Open · 2023-Aug-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial). PMID 37612610 · BMC Cancer · 2023-Aug-23 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER). PMID 37608258 · BMC Cancer · 2023-Aug-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. PMID 37352262 · Blood Adv · 2023-Aug-22 The study is a randomized trial with a drug intervention and includes time-to-event endpoints (OS, relapse). However, the phase is not explicitly stated in the provided metadata (e.g., Phase III). The primary endpoints are incidence-based (aGVHD, mucositis, engraftment), not primary/key secondary time-to-event efficacy endpoints. OS is secondary. Therefore, it does not meet the explicit criterion for a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. PMID 37171402 · Blood Adv · 2023-Aug-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of single versus multiple prophylactic antibiotic doses on prosthetic joint infections following primary total hip arthroplasty in patients with osteoarthritis at public and private hospitals in Denmark: protocol for a nationwide cross-over, cluster randomised, non-inferiority trial [The Pro-Hip-Quality Trial]. PMID 37604637 · BMJ Open · 2023-Aug-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
CBT-based Online Self-help Training to Reduce Fear and Distress After Cancer (CAREST Randomized Trial): 24 Months Follow-up Using Latent Growth Models and Latent Class Analysis. PMID 37078920 · Ann Behav Med · 2023-Aug-21 The study is a randomized trial in an oncology population, but it evaluates a non-drug psychosocial intervention (CBT-based online self-help training) with patient-reported psychological outcomes (distress, fear of recurrence), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of Clinic-Based Patient-Led Human Papillomavirus DNA Self-Sampling among HIV-Infected Women in Uganda. PMID 37623195 · Int J Environ Res Public Health · 2023-Aug-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. PMID 37348019 · J Clin Oncol · 2023-Aug-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. PMID 37315297 · J Clin Oncol · 2023-Aug-20 The study is an oncology randomized trial with a time-to-event endpoint, but it does not involve a drug-containing intervention (it compares radiation techniques). Therefore, it is not eligible for this drug-focused cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. PMID 37207300 · J Clin Oncol · 2023-Aug-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol. PMID 37598200 · Trials · 2023-Aug-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Neo-train: study protocol and feasibility results for a two-arm randomized controlled trial investigating the effect of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer. PMID 37598196 · BMC Cancer · 2023-Aug-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -